The NSABP is a National Cancer Institute funded international multidisciplinary cooperative clinical trial group with over 150 member institutions. The NSABP conducts clinical and other cancer control research concerning the treatment of breast and bowel cancer. Over the past 25 years it has successfully conducted a series of clinical trials, the results of which have dramatically altered the standard care of patients with breast and bowel cancer. The NSABP Biostatistical Center is very experienced in the design, data management and analysis of multi-institutional studies including cancer control trials. The quality control procedures and educational programs for data management are well established. At present, there are six active treatment protocols addressing questions in the adjuvant treatment of primary breast and bowel cancer. The scope of these studies is ideally suited for community investigators who comprise a significant proportion of the current NSABP membership. Twenty CCOP's participate in NSABP trials and in the 12-month period from June, 1985 to May, 1986, they entered 242 patients, 11% of the total group accrual for the same period. These CCOP members have achieved a high standard of data management which is comparable to other member institutions.
The aim of this application is to obtain funds which will allow the NSABP to continue as a CCOP research base and to expand its role by providing not only treatment protocols but cancer control protocols, as well.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA037377-06S1
Application #
3557977
Study Section
Special Emphasis Panel (SRC (46))
Project Start
1983-09-15
Project End
1991-05-31
Budget Start
1989-06-01
Budget End
1991-05-31
Support Year
6
Fiscal Year
1990
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Type
Schools of Medicine
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Saha, Poornima; Regan, Meredith M; Pagani, Olivia et al. (2017) Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. J Clin Oncol 35:3113-3122
Regan, M M; Walley, B A; Francis, P A et al. (2017) Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. Ann Oncol 28:2225-2232
Ternès, Nils; Rotolo, Federico; Michiels, Stefan (2017) Robust estimation of the expected survival probabilities from high-dimensional Cox models with biomarker-by-treatment interactions in randomized clinical trials. BMC Med Res Methodol 17:83
Ribi, Karin; Bernhard, Jürg; Luo, Weixiu et al. (2016) Reply to F. Tomao et al. J Clin Oncol 34:4189-4190
Regan, Meredith M; Francis, Prudence A; Pagani, Olivia et al. (2016) Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. J Clin Oncol 34:2221-31
Phillips, Kelly-Anne; Regan, Meredith M; Ribi, Karin et al. (2016) Adjuvant ovarian function suppression and cognitive function in women with breast cancer. Br J Cancer 114:956-64
Land, Stephanie R; Walcott, Farzana L; Liu, Qing et al. (2016) Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1. J Natl Cancer Inst 108:
Ribi, Karin; Luo, Weixiu; Bernhard, Jürg et al. (2016) Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. J Clin Oncol 34:1601-10
Dalerba, Piero; Sahoo, Debashis; Paik, Soonmyung et al. (2016) CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. N Engl J Med 374:211-22
Johansson, Harriet; Gray, Kathryn P; Pagani, Olivia et al. (2016) Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial. Breast Cancer Res 18:110

Showing the most recent 10 out of 239 publications